The Efficacy of Hydrolyzed Guar Gum ( PHGG) in the Treatment of Patients With Irritable Bowel Syndrome (IBS)
Phase 4
- Conditions
- IBS
- Registration Number
- NCT01779765
- Lead Sponsor
- Tel-Aviv Sourasky Medical Center
- Brief Summary
This study objective is to assess the short and long term effects of partially hydrolyzed guar gum (PHGG) administration on clinical symptoms of IBS and quality of life of these patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 130
Inclusion Criteria
- Fulfillment of the Rome III criteria for IBS.
- Aged 20-68 years at the time of screening.
- Provision of written informed consent.
- Commitment of availability throughout the 6 months study period.
Exclusion Criteria
- Major abdominal surgery in the past.
- The presence of any active (organic)GI disease.
- Past or present major medical or psychiatric illness.
- Any concomitant disease.
- Alarming symptoms (rectal bleeding, weight loss, etc.)
- Pregnancy.
- Family history of colorectal carcinoma or inflammatory bowel disease (IBD).
- Abnormal laboratory studies (blood biochemistry , liver enzymes,complete blood count), abnormal thyroid function.
- Non-adjusted diet in the case of lactose or gluten intolerance.
- Recent travel to regions with endemic parasitic diseases.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Improvement in IBS score. 2 years IBS scoring - Francis severity IBS score.
- Secondary Outcome Measures
Name Time Method Quality questionnaire 2 years Quality of life - by the IBS - quality of life questionnaire - Drossman Patrick.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie PHGG's efficacy in modulating gut microbiota for IBS symptom relief?
How does PHGG compare to standard IBS treatments like linaclotide or eluxadoline in clinical outcomes and safety profiles?
Which biomarkers (e.g., gut microbiota composition, inflammatory cytokines) predict response to PHGG in NCT01779765 IBS trials?
What are the long-term adverse event profiles of PHGG versus other dietary fibers like inulin in IBS patients?
What combination therapies involving PHGG and probiotics show synergistic effects in managing IBS-D or IBS-C subtypes?
Trial Locations
- Locations (1)
Tel Aviv Sourasky Medical Center
🇮🇱Tel Aviv, Israel
Tel Aviv Sourasky Medical Center🇮🇱Tel Aviv, IsraelNachum Vaisman, MDContact972-3-6974807vaisman@tasmc.health.gov.il